Celon Pharma S.A. (WSE:CLN)

Market Cap	1.01B
Revenue (ttm)	225.60M
Net Income (ttm)	-122.39M
Shares Out	53.86M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,171
Average Volume	23,918
Open	18.62
Previous Close	n/a
Day's Range	18.50 - 19.18
52-Week Range	18.50 - 28.65
Beta	0.67
RSI	26.20
Earnings Date	Apr 28, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 558
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 205.55 million, a decrease of -4.25% compared to the previous year's 214.66 million. Losses were -34.45 million, 22.5% more than in 2023.